Cargando…

Pharmaceutical subsidy policy in Iran: a qualitative stakeholder analysis

BACKGROUND: Over the past three decades, allocation of foreign currency subsidies has been the primary strategy of various administrations in Iran to improve access to medicines. This strategy has resulted in several challenges, including stakeholder conflicts of interest. OBJECTIVE: To identify the...

Descripción completa

Detalles Bibliográficos
Autores principales: Olyaaeemanesh, Alireza, Jaafaripooyan, Ebrahim, Abdollahiasl, Akbar, Davari, Majid, Mousavi, Seyyed Meysam, Delpasand, Mansoor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8697451/
https://www.ncbi.nlm.nih.gov/pubmed/34949207
http://dx.doi.org/10.1186/s12961-021-00762-6
_version_ 1784620049336631296
author Olyaaeemanesh, Alireza
Jaafaripooyan, Ebrahim
Abdollahiasl, Akbar
Davari, Majid
Mousavi, Seyyed Meysam
Delpasand, Mansoor
author_facet Olyaaeemanesh, Alireza
Jaafaripooyan, Ebrahim
Abdollahiasl, Akbar
Davari, Majid
Mousavi, Seyyed Meysam
Delpasand, Mansoor
author_sort Olyaaeemanesh, Alireza
collection PubMed
description BACKGROUND: Over the past three decades, allocation of foreign currency subsidies has been the primary strategy of various administrations in Iran to improve access to medicines. This strategy has resulted in several challenges, including stakeholder conflicts of interest. OBJECTIVE: To identify the power, interest, and role of the stakeholders in allocating foreign currency subsidies to medicines in the Iranian health system. METHODS: In this qualitative study, 39 semi-structured interviews were conducted. Key informants were recruited using a purposive sampling technique. The theoretical framework adopted by Varvasovszky and Brugha was employed. The data were analysed using directed content analysis. RESULTS: The foreign currency subsidy for medicines included 21 stakeholders in five main categories: governmental organizations, Iranian Parliament, general population, nongovernmental organizations (NGOs), and the pharmaceutical industry. Stakeholders varied in their level of participation and support in the policy-making process. Among them, the Iranian Government, Planning and Budget Organization, the Ministry of Health and Medical Education (MoHME), and Iran Food and Drug Administration (IFDA) were the most important stakeholders, with highly supportive positions, while domestic drug manufacturers were the strongest opponents of this policy. The Government of Iran is the most powerful institution with regard to the ability to allocate foreign currency subsidies to medicines, followed by the MoHME and the IFDA. CONCLUSION: This study demonstrated that identifying and analysing the stakeholders involved in allocating foreign currency subsidies to medicines can provide valuable information for policy-makers to enable a more comprehensive understanding and better capacity to determine whether or not to eliminate these subsidies. Moreover, decision-making in this process is a long-term issue that requires consensus among all stakeholders. Because of the political and social consequences of eliminating foreign currency subsidies, the necessary political will is not institutionalized. We recommend a step-by-step approach in eliminating foreign currency subsidies if the requirements are met (i.e., those related to the consequences of such interventions). Therefore, revision of the current policy along with these requirements, in addition to financial transparency and enhanced efficiency, will facilitate progress towards achieving the Sustainable Development Goals by improving access to medicines. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12961-021-00762-6.
format Online
Article
Text
id pubmed-8697451
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86974512022-01-05 Pharmaceutical subsidy policy in Iran: a qualitative stakeholder analysis Olyaaeemanesh, Alireza Jaafaripooyan, Ebrahim Abdollahiasl, Akbar Davari, Majid Mousavi, Seyyed Meysam Delpasand, Mansoor Health Res Policy Syst Research BACKGROUND: Over the past three decades, allocation of foreign currency subsidies has been the primary strategy of various administrations in Iran to improve access to medicines. This strategy has resulted in several challenges, including stakeholder conflicts of interest. OBJECTIVE: To identify the power, interest, and role of the stakeholders in allocating foreign currency subsidies to medicines in the Iranian health system. METHODS: In this qualitative study, 39 semi-structured interviews were conducted. Key informants were recruited using a purposive sampling technique. The theoretical framework adopted by Varvasovszky and Brugha was employed. The data were analysed using directed content analysis. RESULTS: The foreign currency subsidy for medicines included 21 stakeholders in five main categories: governmental organizations, Iranian Parliament, general population, nongovernmental organizations (NGOs), and the pharmaceutical industry. Stakeholders varied in their level of participation and support in the policy-making process. Among them, the Iranian Government, Planning and Budget Organization, the Ministry of Health and Medical Education (MoHME), and Iran Food and Drug Administration (IFDA) were the most important stakeholders, with highly supportive positions, while domestic drug manufacturers were the strongest opponents of this policy. The Government of Iran is the most powerful institution with regard to the ability to allocate foreign currency subsidies to medicines, followed by the MoHME and the IFDA. CONCLUSION: This study demonstrated that identifying and analysing the stakeholders involved in allocating foreign currency subsidies to medicines can provide valuable information for policy-makers to enable a more comprehensive understanding and better capacity to determine whether or not to eliminate these subsidies. Moreover, decision-making in this process is a long-term issue that requires consensus among all stakeholders. Because of the political and social consequences of eliminating foreign currency subsidies, the necessary political will is not institutionalized. We recommend a step-by-step approach in eliminating foreign currency subsidies if the requirements are met (i.e., those related to the consequences of such interventions). Therefore, revision of the current policy along with these requirements, in addition to financial transparency and enhanced efficiency, will facilitate progress towards achieving the Sustainable Development Goals by improving access to medicines. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12961-021-00762-6. BioMed Central 2021-12-23 /pmc/articles/PMC8697451/ /pubmed/34949207 http://dx.doi.org/10.1186/s12961-021-00762-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Olyaaeemanesh, Alireza
Jaafaripooyan, Ebrahim
Abdollahiasl, Akbar
Davari, Majid
Mousavi, Seyyed Meysam
Delpasand, Mansoor
Pharmaceutical subsidy policy in Iran: a qualitative stakeholder analysis
title Pharmaceutical subsidy policy in Iran: a qualitative stakeholder analysis
title_full Pharmaceutical subsidy policy in Iran: a qualitative stakeholder analysis
title_fullStr Pharmaceutical subsidy policy in Iran: a qualitative stakeholder analysis
title_full_unstemmed Pharmaceutical subsidy policy in Iran: a qualitative stakeholder analysis
title_short Pharmaceutical subsidy policy in Iran: a qualitative stakeholder analysis
title_sort pharmaceutical subsidy policy in iran: a qualitative stakeholder analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8697451/
https://www.ncbi.nlm.nih.gov/pubmed/34949207
http://dx.doi.org/10.1186/s12961-021-00762-6
work_keys_str_mv AT olyaaeemaneshalireza pharmaceuticalsubsidypolicyiniranaqualitativestakeholderanalysis
AT jaafaripooyanebrahim pharmaceuticalsubsidypolicyiniranaqualitativestakeholderanalysis
AT abdollahiaslakbar pharmaceuticalsubsidypolicyiniranaqualitativestakeholderanalysis
AT davarimajid pharmaceuticalsubsidypolicyiniranaqualitativestakeholderanalysis
AT mousaviseyyedmeysam pharmaceuticalsubsidypolicyiniranaqualitativestakeholderanalysis
AT delpasandmansoor pharmaceuticalsubsidypolicyiniranaqualitativestakeholderanalysis